Johnson & Johnson will pursue U.S. approval for the world’s first pill to treat premature ejaculation after tests on 6,000 men showed it more than tripled the time before they reached climax.
J&J will discuss approval with the Food and Drug Administration later this year, Joanne Waldstreicher, chief medical officer at the New Brunswick, New Jersey-based company, told investors and analysts today. The FDA rejected the drug in 2005. Since then, J&J has conducted three additional human trials, doubling the number of patients tested for safety and effectiveness.
The drug, sold as Priligy in Europe, is taken a few hours before intercourse to increase the time before the patient ejaculates. The drug was originally developed by Eli Lilly & Co., of Indianapolis, as a potential antidepressant and was acquired by J&J. The company also seeks to sell the pill in Australia, Canada, Mexico, Turkey and six other countries.
No comments:
Post a Comment